Erratum: Relationship between enzyme properties and disease progression in canavan disease (J Inherit Metab Dis, (2013) 36, 1 (1-6), 10.1007/s10545-012-9520-z);Relationship between enzyme properties and disease progression in Canavan disease

Journal of Inherited Metabolic Disease

Volumn 36, Issue 1, 2013, Pages 1-6

  Zano, Stephen ^a   Wijayasinghe, Yasanandana S ^a   Malik, Radhika ^a,b   Smith, Joshua ^a   Viola, Ronald E ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTOACYLASE; MUTANT PROTEIN; N ACETYLASPARTIC ACID;

ARTICLE; ASPA GENE; BIOACCUMULATION; BRAIN DEVELOPMENT; CANAVAN DISEASE; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME DEFECT; ENZYME PURIFICATION; ENZYME STABILITY; GENE; LOSS OF FUNCTION MUTATION; NONHUMAN; PHENOTYPE; PICHIA PASTORIS; PROTEIN FUNCTION; THERMODYNAMICS;

EID: 84872595092     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9554-2     Document Type: Erratum

References (27)

1. Adachi M, Schneck L, Cara J, Volk BW (1973) Spongy degeneration of the central nervous system (Van Bogaert and Bertrand type; Canavan's disease). Human Pathol 4:331-347
2. Adornato BT, O'Brien JS, Lampert PW, Roe TF, Neustein HB (1972) Cerebral spongy degeneration of infancy: a biochemical and ultrastructural study of affected twins. Neurology 22:202-210
3. Almarza J, Rincon L, Bahsas A, Brito F (2009) Molecular mechanism for the denaturation of proteins by urea. Biochemistry 48:7608-7613
4. Canavan MM (1931) Schindler's Encephalitis Periaxialis Diffusa. Arch Neurol Psychiat 25:299-308
5. Elpeleg ON, Shaag A (1999) The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients. J Inher Metabol Dis 22:531-544
6. Globus JH, Strauss I (1928) Progressive degenerative subcortical encephalophaty (Schilder's disease). Arch Neurol Psychiat 20:1190-1228
7. Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for canavan disease. Brain Res 1148:1-14
8. Janson CG, Kolodny EH, Zeng BJ, Raghavan S, Pastores GM, Torres P et al. (2006) Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Ann Neurol 59:428-431
9. Karsten WE, Hunsley JR, Viola RE (1985) Purification of aspartase and aspartokinase-homoserine dehydrogenase I from Escherichia coli by Dye-Ligand chromatography. Anal Biochem 147:336-341
10. Kaul R, Balamurugan K, Gao GP, Matalon R (1994a) Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 21:364-370
11. Kaul R, Gao GP, Aloya M, Balamurugan K, Petrosky A, Michals-Matalon K et al. (1994b) Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet 55:34-41
12. Kaul R, Gao GP, Michals-Matalon K, Whelan DT, Levin S, Matalon R (1995) Novel (cys152 > arg) missense mutation in an Arab patient with Canavan disease. Hum Mutat 5:269-271
13. Kobayashi, K, Tsujino, S, Ezoe, T, Hamaguchi, H, Nihei, K, Sakuragawa, N (1998) Missense mutation (I143T) in a Japanese patient with Canavan disease. Human Mutation S308-S309
14. Le Coq J, An HJ, Lebrilla CB, Viola RE (2006) Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease. Biochemistry 45:5878-5884
15. Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47:3484-3492
16. Lim WK, Rosgen J, Englander SW (2009) Urea, but not guanidinium, destabilizes proteins by forming hydrogen bonds to the peptide group. Proc Natl Acad Sci USA 106:2595-2600
17. Matalon R, Kaul R, Michals K (1993) Canavan disease: biochemical and molecular studies. J Inher Metabol Dis 16:744-752
18. Matalon R, Michals-Matalon K, Sebesta M, Deanching M, Gashkoff P, Casanova J (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 29:463-471
19. Moore RA, Le Coq J, Faehnle CR, Viola RE (2003) Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 413:1-8
20. Shaag A, Anikster Y, Christensen E, Glustein JZ, Fois A, Michelakakis H et al. (1995) The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 57:572-580
21. Surendran S, Bamforth FJ, Chan A, Tyring SK, Goodman SI, Matalon R (2003) Mild elevation of N-Acetylaspartic acid and macrocephaly: diagnostic problem. J Child Neurol 18:809-812
22. Tacke U, Olbrich H, Sass JO, Fekete A, Horvath J, Ziyeh S et al. (2005) Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 36:252-255
23. Traeger EC, Rapin I (1998) The clinical course of Canavan disease. Pediatr Neurol 18:207-212
24. van Bogaert L, Bertrand L (1949) Sur une idiotie familiale avec dégénérescence spongieuse du névraxe. Acta Neur Psychiatr Belg 49:572-585
25. Yalcinkaya C, Benbir G, Salomons GS, Karaarslan E, Rolland MO, Jakobs C et al. (2005) Atypical MRI findings in Canavan disease: a patient with a mild course. Neuropediatrics 36:336-339
26. Zeng BJ, Wang ZH, Ribeiro LA, Leone P, De Gasperi R, Kim SJ et al. (2002) Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inher Metabol Dis 25:557-570
27. Zhang H, Liu X, Gu X (2010) Two novel missense mutations in the aspartoacylase gene in a Chinese patient with congenital Canavan disease. Brain Dev 32:879-882